- Home
- MRCC vs ACTU Comparison
MRCC vs ACTU Comparison
Compare MRCC & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- ACTU
- Stock Information
- Founded
- MRCC 2011
- ACTU 2015
- Country
- MRCC United States
- ACTU United States
- Employees
- MRCC N/A
- ACTU N/A
- Industry
- MRCC Investment Managers
- ACTU
- Sector
- MRCC Finance
- ACTU
- Exchange
- MRCC Nasdaq
- ACTU NYSE
- Market Cap
- MRCC 174.8M
- ACTU 153.1M
- IPO Year
- MRCC 2012
- ACTU 2024
- Fundamental
- Price
- MRCC $8.21
- ACTU $7.66
- Analyst Decision
- MRCC Strong Buy
- ACTU
- Analyst Count
- MRCC 1
- ACTU 0
- Target Price
- MRCC $9.00
- ACTU N/A
- AVG Volume (30 Days)
- MRCC 71.5K
- ACTU 67.4K
- Earning Date
- MRCC 11-12-2024
- ACTU 11-13-2024
- Dividend Yield
- MRCC 12.15%
- ACTU N/A
- EPS Growth
- MRCC 298.01
- ACTU N/A
- EPS
- MRCC 0.60
- ACTU N/A
- Revenue
- MRCC $62,007,000.00
- ACTU N/A
- Revenue This Year
- MRCC N/A
- ACTU N/A
- Revenue Next Year
- MRCC N/A
- ACTU N/A
- P/E Ratio
- MRCC $13.71
- ACTU N/A
- Revenue Growth
- MRCC N/A
- ACTU N/A
- 52 Week Low
- MRCC $6.77
- ACTU $5.51
- 52 Week High
- MRCC $8.74
- ACTU $10.16
- Technical
- Relative Strength Index (RSI)
- MRCC 42.18
- ACTU N/A
- Support Level
- MRCC $8.37
- ACTU N/A
- Resistance Level
- MRCC $8.66
- ACTU N/A
- Average True Range (ATR)
- MRCC 0.19
- ACTU 0.00
- MACD
- MRCC -0.05
- ACTU 0.00
- Stochastic Oscillator
- MRCC 1.85
- ACTU 0.00
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.